Why Halozyme Therapeutics, Inc. (HALO) Stock Fell 15.7% on Nov 6, 2026
What happened
Halozyme fell 13.31% to $106.59 after the FDA approved RYBREVANT FASPRO co-formulated with the company's ENHANZE® technology for advanced head and neck cancer (PR Newswire), and the company reaffirmed minimal royalty revenue impact from Medicare drug price negotiations through 2035. Despite positive regulatory and program-impact news, the stock declined sharply on elevated volume of 5.19x normal levels 80 minutes into the session, suggesting investor disappointment with either the approval scope or guidance implications.
Halozyme earnings scheduled for February 16, 2027 (consensus EPS estimate $2.56); monitor for any analyst notes or conference call commentary on royalty revenue trajectory and ENHANZE pipeline execution.
Other developments that session
Halozyme reaffirms zero to minimal royalty revenue impact through 2035 from Medicare drug price negotiation program.
Frequently asked questions
Why did Halozyme Therapeutics, Inc. (HALO) stock fall on Nov 6, 2026?
Halozyme fell 13.31% to $106.59 after the FDA approved RYBREVANT FASPRO co-formulated with the company's ENHANZE® technology for advanced head and neck cancer (PR Newswire), and the company reaffirmed minimal royalty revenue impact from Medicare drug price negotiations through 2035. Despite positive regulatory and program-impact news, the stock declined sharply on elevated volume of 5.19x normal levels 80 minutes into the session, suggesting investor disappointment with either the approval scope or guidance implications.
How much did HALO stock fall on Nov 6, 2026?
HALO fell 15.7% during the Nov 6, 2026 trading session.